Version 1
: Received: 27 November 2023 / Approved: 28 November 2023 / Online: 29 November 2023 (04:53:56 CET)
How to cite:
FERRARI, I.V. Molecular Insights into Hypericin: Unraveling its Theoretical Potential in Alzheimer's Disease Intervention. Preprints2023, 2023111768. https://doi.org/10.20944/preprints202311.1768.v1
FERRARI, I.V. Molecular Insights into Hypericin: Unraveling its Theoretical Potential in Alzheimer's Disease Intervention. Preprints 2023, 2023111768. https://doi.org/10.20944/preprints202311.1768.v1
FERRARI, I.V. Molecular Insights into Hypericin: Unraveling its Theoretical Potential in Alzheimer's Disease Intervention. Preprints2023, 2023111768. https://doi.org/10.20944/preprints202311.1768.v1
APA Style
FERRARI, I.V. (2023). Molecular Insights into Hypericin: Unraveling its Theoretical Potential in Alzheimer's Disease Intervention. Preprints. https://doi.org/10.20944/preprints202311.1768.v1
Chicago/Turabian Style
FERRARI, I.V. 2023 "Molecular Insights into Hypericin: Unraveling its Theoretical Potential in Alzheimer's Disease Intervention" Preprints. https://doi.org/10.20944/preprints202311.1768.v1
Abstract
BACE1 is involved in the production of beta-amyloid peptides, and inhibiting its activity is a potential therapeutic strategy for managing Alzheimer's disease, as excessive beta-amyloid accumulation is a characteristic feature of the disease.Computational results suggest that hypericin has the potential to act as an inhibitor of BACE1. The Molecular Docking results indicate a high binding affinity between hypericin and BACE1, with a notable binding energy score of -10.3 kcal/mol. Additionally, the formation of various chemical bonds, including hydrogen bonds and hydrophobic bonds, further supports the idea that hypericin may effectively interact with the active site of BACE1. It's important to note that while the in silico Molecular Docking results are promising, further in vitro and in vivo studies would be necessary to validate and better understand the inhibitory potential of hypericin against BACE1. Additionally, the practical application of hypericin as a BACE1 inhibitor in a therapeutic context would require careful consideration of factors such as bioavailability, safety, and efficacy.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
